Literature DB >> 2784546

Positron emission tomography in the detection of malignant degeneration of low-grade gliomas.

T L Francavilla1, R S Miletich, G Di Chiro, N J Patronas, H V Rizzoli, D C Wright.   

Abstract

The management of low-grade gliomas represents a challenge to the physician as a significant proportion may undergo malignant degeneration to a high-grade tumor. We present the positron emission tomography (PET) scans, using [18F] fluorodeoxyglucose (FDG), of 12 patients who have histological and/or clinical evidence of malignant degeneration of a low-grade glioma. Each scan displays a focal area of hypermetabolism similar to that of malignant gliomas which arise de novo. Three patients also underwent PET scanning prior to malignant degeneration. When the initial scan is compared with the postmalignant degeneration study, a difference in tumoral glucose uptake can be recognized. A region previously shown to be hypometabolic develops focal hypermetabolism as malignant changes evolve. This study displays the utility of FDG-PET in the evaluation of malignant degeneration of low-grade gliomas. The knowledge that a neoplasm has altered its biological behavior may influence subsequent therapeutic options. If these findings can be confirmed in larger series and by other investigators, it is possible that FDG-PET may be adopted as one of the diagnostic tools for guiding the management of low-grade gliomas.

Entities:  

Mesh:

Year:  1989        PMID: 2784546     DOI: 10.1227/00006123-198901000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

Review 1.  Positron emission tomography and the central nervous system.

Authors:  R O Robinson; C D Ferrie; M Capra; M N Maisey
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

Review 2.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

3.  Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.

Authors:  Michail Plotkin; C Blechschmidt; G Auf; F Nyuyki; L Geworski; T Denecke; W Brenner; F Stockhammer
Journal:  Eur Radiol       Date:  2010-06-03       Impact factor: 5.315

4.  ¹⁸F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma.

Authors:  Jun Hatazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05       Impact factor: 9.236

Review 5.  The role of surgery in low grade gliomas.

Authors:  J Bampoe; M Bernstein
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 6.  Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

Authors:  C S Brock; S R Meikle; P Price
Journal:  Eur J Nucl Med       Date:  1997-06

7.  Histological heterogeneity of neuroradiologically suspected adult low grade gliomas detected by Xenon enhanced computerized tomography (CT).

Authors:  K Roessler; C Nasel; T Czech; C Matula; H Lassmann; W T Koos
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

Review 8.  The role of SPET and PET in monitoring tumour response to therapy.

Authors:  Chariklia Giannopoulou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-14       Impact factor: 9.236

9.  Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi.

Authors:  G Baillet; L Albuquerque; Q Chen; M Poisson; J Y Delattre
Journal:  Eur J Nucl Med       Date:  1994-10

Review 10.  Current perspectives in gliomas.

Authors:  C S Brock; M Bower
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.